Skip to main content
TGTX
NASDAQ Life Sciences

TG Therapeutics Q2 BRIUMVI Revenue Hits $228M, Refinances Debt with $750M Term Loan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$50.479
Mkt Cap
$7.636B
52W Low
$25.28
52W High
$59.3
52W Position info
100% above low
Off High info
15% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

TGTX sits 100% above its 52-week low of $25.28.

Summary

TG Therapeutics reported Q2 2026 BRIUMVI U.S. revenue of $227.7M (+64% YoY), raised full-year guidance to ~$950M, refinanced debt with a $750M term loan, and announced positive clinical data for next-generation BRIUMVI formulations.


Key Events · Earnings and Guidance · TGTX

  • BRIUMVI Revenue Surges 64%

    Q2 2026 BRIUMVI U.S. net product revenue reached $227.7 million, up from $138.8 million in Q2 2025, driven by strong market penetration. Total revenue was $240.3 million, with net income of $7.8 million.

  • Full-Year Guidance Raised to ~$950M

    Management raised full-year 2026 total revenue guidance to approximately $950 million, reflecting confidence in continued BRIUMVI growth and ex-U.S. royalties.

  • $750M Term Loan Refinancing

    The company replaced its $250 million term loan with a new $750 million facility maturing in 2031, improving liquidity and extending debt maturity. A $9.2 million loss on extinguishment was recorded in Q1 2026.

  • Share Repurchase Program Expanded to $300M

    The board increased the share repurchase authorization from $100 million to $300 million. Through June 30, 2026, $100 million of stock had been repurchased at an average price of $30.44 per share.


Analysis · TGTX · Life Sciences

TG Therapeutics delivered strong Q2 2026 results with BRIUMVI U.S. net revenue of $227.7 million, up 64% year-over-year, and raised full-year guidance to approximately $950 million. The company refinanced its $250 million term loan with a larger $750 million facility, extending maturity to 2031 and providing ample liquidity. Positive clinical data for a single-infusion BRIUMVI regimen and subcutaneous formulation support lifecycle management, while a $300 million share repurchase authorization signals confidence. The combination of accelerating commercial execution, pipeline progress, and a strengthened balance sheet makes this a highly important update for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TGTX was trading at $50.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $25.28 to $59.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TGTX - Latest Insights

TGTX
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $63.54
Real-time Price: $63.21 info
Change: -$0.3272 (-0.51%) info
Market Cap: $9.574B info
TGTX
Nov 09, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $63.55
Real-time Price: $63.21 info
Change: -$0.340 (-0.54%) info
Market Cap: $9.574B info
TGTX
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.00
Real-time Price: $63.21 info
Change: +$0.210 (+0.33%) info
Market Cap: $9.574B info
TGTX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $58.11
Real-time Price: $63.21 info
Change: +$5.10 (+9%) info
Market Cap: $9.574B info
TGTX
Oct 23, 2026, 11:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.44
Real-time Price: $63.21 info
Change: +$10.77 (+21%) info
Market Cap: $9.574B info